All In Biotech

Drug Trial Radar · NCT05016882

Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

Efficacy and Safety Investigation of NNC0194-0499 Co-administered With Semaglutide in Subjects With Non-alcoholic Steatohepatitis: a Dose-ranging, Placebo Controlled Trial

Last checked: Nov 19, 2026Latest source record: Nov 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 698 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

698

Actual

Start

Aug 31, 2021

Primary completion

Dec 17, 2024

Study completion Mar 14, 2025

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Aug 23, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being done to see if a combination of 2 medicines (called NNC0194-0499 and semaglutide) can reduce liver damage in patients with non alcoholic steatohepatitis (NASH). NNC0194-0499 is a new medicine which works in the liver. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries. It also helps with weight loss and may reduce liver damage, and so prevent future liver complications. It works in a different way to NNC0194 0499. The 2 medicines may work better together than on their own. The study will also look at a combination of semaglutide and another weight-loss medicine called NNC0174-0833, which may be another treatment option for NASH. Each week, participants will get 2 injections. These could be 2 of the 3 medicines OR 1 of the medicines and a placebo OR 2 placebo injections. Which treatment participants get is decided by chance. A placebo is a dummy medicine which looks like the real medicine but doesn't contain any active medicine. The study will last for about 19 months. Participants will have 14 clinic visits and 9 phone calls with the study doctor. Participants will have 1 or 2 liver biopsies (tiny pieces of liver tissue) - one at the start (if participants have not had a biopsy recently) and one at the end of the study treatment. Women: Women cannot take part if pregnant, breast-feeding or planning to become pregnant during the study period.

Conditions

  • Non-alcoholic Steatohepatitis

Interventions

  • NNC0194 0499 50 mg/mLDrug

    Patients will receive subcutaneous (s.c., under the skin) injections of NNC0194-0499 once weekly The study will last for about 19 months

  • Placebo (NNC0194-0499)Drug

    Patients will receive subcutaneous (s.c., under the skin) injections of placebo once weekly The study will last for about 19 months

  • Semaglutide 3 mg/mLDrug

    Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide once weekly The study will last for about 19 months

  • Semaglutide placeboDrug

    Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide placebo once weekly The study will last for about 19 months

  • NNC0174 0833 10 mg/mLDrug

    Patients will receive subcutaneous (s.c., under the skin) injections of NNC0174-0833 once weekly The study will last for about 19 months

  • NNC0174 0833 placeboDrug

    Patients will receive subcutaneous (s.c., under the skin) injections of NNC0174-0833 placebo once weekly The study will last for about 19 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Improvement in liver fibrosis and no worsening of NASH (Yes/No)Time frame: From baseline (week 0) to week 52

Locations

255 sites in 24 countries. Site status is shown where the registry gives one.

  • North AL Health Res, LLC

    Huntsville, Alabama

  • The Institute for Liver Health

    Chandler, Arizona

  • Inst-Liver Hlth dba AZ Liver H

    Peoria, Arizona

  • Del Sol Research Management, LLC

    Tucson, Arizona

  • Hope Clinical Research

    Canoga Park, California

  • UCSD NAFLD Research Center

    La Jolla, California

  • OM Research LLC

    Lancaster, California

  • Digestive Hlth Res of SoCa

    Long Beach, California

  • Stanford Medicine

    Redwood City, California

  • UC Davis Hlth -Midtwn Ambu Cen

    Sacramento, California

  • Peak Gastro Assoc-Col Springs

    Colorado Springs, Colorado

  • Hartford Hsptl_Hartford

    Hartford, Connecticut

  • Integrity Clinical Research, LLC

    Doral, Florida

  • Miguel Rebollar PA

    Hialeah, Florida

  • Nature Coast Clinical Research_Inverness

    Inverness, Florida

  • UF Hlth Jacksonville

    Jacksonville, Florida

  • Florida Research Institute, LLC

    Lakewood Rch, Florida

  • ClinCloud,LLC

    Maitland, Florida

  • Optimus U, Corp

    Miami, Florida

  • Univ of Miami/Schiff Ctr

    Miami, Florida

  • Covenant Metabolic Specialists LLC

    University Park, Florida

  • ClinCloud, LLC

    Viera E., Florida

  • Florida Medical Clinic Orlando Health

    Zephyrhills, Florida

  • Florida Medical Clinic, LLC

    Zephyrhills, Florida

  • Piedmont Healthcare

    Atlanta, Georgia

  • Digestive Healthcare of Georgia

    Atlanta, Georgia

  • Gastroenterology Assoc_ CGA

    Macon, Georgia

  • Gastroint Spec of Georgia

    Marietta, Georgia

  • EBGS Clinical Research Center, LLC

    Snellville, Georgia

  • Grand Teton Gastroenterology

    Idaho Falls, Idaho

  • Digestive Research Alliance of Michiana

    South Bend, Indiana

  • University Of Kansas Hospital

    Kansas City, Kansas

  • Kansas Medical Clinic, PA

    Topeka, Kansas

  • Tandem Clinical Research - Houma

    Houma, Louisiana

  • Tandem Clinical Research

    Marrero, Louisiana

  • Tandem Clinical Research - Metairie

    Metairie, Louisiana

  • Louisiana Research Center, LLC

    Shreveport, Louisiana

  • Mercy Medical Center, GI Research

    Baltimore, Maryland

  • Walter Reed Nat Mil Md Ctr

    Bethesda, Maryland

  • Henry Ford Hospital_Detroit

    Detroit, Michigan

Showing 40 of 255 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.